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€-1335.30, the largest difference was due to the length
of hospital stay (€-1468.50). The surgical procedure was
the only item that resulted in more resource consumption
in the TVT procedure (differential cost per patient of
€158.29). Sensitivity analyses showed that even in the
case where the TVT patients are hospitalized for 3 days,
the TVT procedure remains the least resource consuming
and the least costly option (differential cost per patient of
€-513.80). CONCLUSIONS: The TVT procedure proved
to be more efﬁcient than the OBC option in the surgical
treatment of female SUI.
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OBJECTIVE: This analysis addresses the cost-
effectiveness of the new extended release formulation
(XL) of Ditropan (oxybutynin) for the treatment of over-
active bladder relative to immediate release Detrol
(tolterodine), if the drugs are priced equivalently.
METHODS: A state-transition model was developed to
compare health economic outcomes over the course of
one year. Effectiveness and treatment persistence data
were derived from the OBJECT trial, a 3-month ran-
domized, double-blind study comparing Ditropan XL 10
mg with Detrol 4mg and used, together with data from
the literature to project outcomes beyond the trial time.
Severity-speciﬁc cost proﬁles for incontinence were devel-
oped for the province of Ontario, and are reported in
2002 Canadian dollars. In the principal analyses, only
direct costs were included and were limited to drug price,
physician visits, and pad or protection usage. RESULTS:
Ditropan XL is predicted to be the dominant therapeutic
option, with higher effectiveness and lower overall costs
than Detrol. After 1 year, total costs are expected to be
an average of $32 lower per patient with Ditropan XL,
while 3.15 more patients per 100 treated attain complete
continence (20.4% versus 17.2%). As well, more patients
treated with Ditropan XL have less than 7 incontinent
episodes per week. Over the course of the year, patients
on Ditropan XL are expected to have an average of 16
additional incontinence-free days. Results are most sensi-
tive to relative drug prices, with a price differential of only
$0.11 per day required for savings with Ditropan XL to
be eliminated. In other sensitivity analyses, however,
Ditropan XL maintained its advantage over wide ranges
of inputs. CONCLUSION: These analyses suggest that,
at price parity, Ditropan XL provides better results than
Detrol over 1 year and reduces costs.
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OBJECTIVES: The safety and efﬁcacy of Renagel® (seve-
lamer hydrochloride) in binding phosphate in patients
with end stage renal disease and its ability to attenuate
the progression of cardiac calciﬁcation has been well doc-
umented but not the longer-term health and economic
consequences. Thus, a model of the predicted long-
term consequences of Renagel® compared to calcium-
based binders (acetate and carbonate) was developed.
METHODS: Long-term cardiovascular implications of
one year of treatment with phosphate binders in patients
on hemodialysis are estimated based on the patient’s
demographics, co-morbidities, and physiologic and renal
parameters. The initial calciﬁcation score and expected
changes over one year are derived using regression equa-
tions developed from the Treat-to-Goal study and trans-
lated to cardiovascular disease risk based on equations
developed from a long-term cohort study (London). The
implications of cardiovascular disease for life expectancy
and medical costs are accounted for from a US payer per-
spective. RESULTS: In a population of 100 patients, the
cardio-protective effect of Renagel® over 1 year is esti-
mated to prevent 9 future cardiovascular events and to
save 18 life years compared with calcium acetate; and 10
events and 18 life years compared to carbonate. These
events would cost $205,600 and $226,700 to manage.
These beneﬁts are obtained at a net cost of about $37,900
and $19,500, respectively. The incremental cost-
effectiveness ratios amount to $2200 and $1100 per 
(discounted) life year gained; and $4400 and $2300 per
cardiovascular event prevented. CONCLUSIONS: Wide-
spread use of Renagel® for treatment of hyperphos-
phatemia in patients on hemodialysis may seem like just
another burden on already strained health care resources.
In the context of dialysis, at a median cost-effectiveness
ratio of $46,000 per life year gained, the results of this
study provide evidence that such intervention would be
economically sound.
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